Leo Hansmann
Overview
Explore the profile of Leo Hansmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsu M, Willimsky G, Hansmann L, Blankenstein T
Front Immunol
. 2025 Feb;
16:1518691.
PMID: 39931057
BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. Although...
2.
Stadler S, Blasco R, Singh V, Damm-Welk C, Ben-Hamza A, Welters C, et al.
Cancer Immunol Res
. 2025 Jan;
PMID: 39774774
Anaplastic lymphoma kinase (ALK)-fusion proteins resulting from chromosomal rearrangements are promising targets for cancer immunotherapy. While ALK-specific CD8+ T cells and epitopes presented on MHC class I have been identified...
3.
Perl M, Herfeld K, Harrer D, Hopting M, Schweiger M, Sterz U, et al.
Haematologica
. 2024 Mar;
109(9):2969-2977.
PMID: 38546698
Chimeric antigen receptor (CAR) T-cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that has up to now been considered the result...
4.
Welters M, Stadler S, Anastasopoulou V, Bullinger L, Leisegang M, Kammertons T, et al.
Eur J Immunol
. 2024 Mar;
54(6):e2350908.
PMID: 38501894
We demonstrate an optimized oligonucleotide library-based approach for the identification of virus-reactive T-cell receptors using Epstein-Barr virus as an example. HEK293T served as antigen-presenting cells and were co-cultured with human...
5.
Ben Hamza A, Welters C, Stadler S, Bruggemann M, Dietze K, Brauns O, et al.
Blood
. 2024 Jan;
143(14):1365-1378.
PMID: 38277625
Acquired aplastic anemia is a bone marrow failure syndrome characterized by hypocellular bone marrow and peripheral blood pancytopenia. Frequent clinical responses to calcineurin inhibition and antithymocyte globulin strongly suggest critical...
6.
Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, et al.
Front Immunol
. 2023 Nov;
14:1251593.
PMID: 37965339
Introduction: Allogeneic stem cell transplantation is used to cure hematologic malignancies or deficiencies of the hematopoietic system. It is associated with severe immunodeficiency of the host early after transplant and...
7.
Welters C, Welters M, Stadler S, Bullinger L, Strobel J, Hackstein H, et al.
Haematologica
. 2023 Sep;
109(4):1121-1127.
PMID: 37767552
The null allele HLA-C*04:09N differs from HLA-C*04:01 in a frameshift mutation within its cytoplasmic domain, resulting in translation of 32 additional amino acids that are assumed to prevent cell surface...
8.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H, et al.
J Clin Invest
. 2023 May;
133(12).
PMID: 37159273
BACKGROUNDAdoptive transfer of EBV-specific T cells can restore specific immunity in immunocompromised patients with EBV-associated complications.METHODSWe provide results of a personalized T cell manufacturing program evaluating donor, patient, T cell...
9.
Welters C, Lammoglia Cobo M, Stein C, Hsu M, Ben Hamza A, Penter L, et al.
Cancer Immunol Res
. 2022 Sep;
10(11):1407-1419.
PMID: 36122410
Multiple myeloma is a hematologic malignancy of monoclonal plasma cells that accumulate in the bone marrow. Despite their clinical and pathophysiologic relevance, the roles of bone marrow-infiltrating T cells in...
10.
Ballhausen A, Ben Hamza A, Welters C, Dietze K, Bullinger L, Rahn H, et al.
Cancer Immunol Immunother
. 2022 Aug;
72(2):515-521.
PMID: 35947165
Lymph node-infiltrating T cells have been of particular interest in classical Hodgkin lymphoma (cHL). High rates of complete therapeutic responses to antibody-mediated immune checkpoint blockade, even in relapsed/refractory patients, suggest...